Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 47 | 0.91 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 5408
Sealed predictions
- KANK2 in dopamine neurons, braak-0.37 (p 0.323) → -0.26 (p 0.493)receipt 5415
Swarm cases
receipt 5415: KANK2 in dopamine neurons, braak
- power
- full sample -0.21 (p 0.403, n 18), 95% CI -0.62 to +0.28. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.24 (p 0.341, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.33 (p 0.188, n 18). could be the mix.
- skeptic
- leave-one-out range -0.36 to -0.10, sign flips 0; without severely affected donors -0.21 (p 0.403, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.61 (p 0.0067, n 18) vs -0.21 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for KANK2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up KANK2 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.05 p 0.859 (needs p < 3.7e-4)
Receipts
loading the receipts